ArticleJournal of Zhejiang University. Science. B2025
Drug-assisted synthesis of copper nanoparticles and their induction of cuproptosis and necrosis for breast cancer therapy.
Article in Journal of Zhejiang University. Science. B, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Neurokinin-1 receptor (NK1R), a member of the G protein-coupled receptor (GPCR) family, contributes to multiple pathological processes, including pain, chronic inflammation, and cancer (Gutierrez et al., 2019; Robinson et al., 2023). Current reports and our previous work have proven that NK1R is highly expressed in many cancer cells, such as colorectal cancer and leukemia, and that targeted blocking of NK1R can effectively inhibit tumor cell proliferation (Li XQ et al., 2013; Li JY et al., 2016; Ge et al., 2019; Shi et al., 2021). In addition, GPCRs have been found not only in the plasma membrane but also in the membranes of endosomes and lysosomes with endocytosis (Irannejad et al., 2017; Yarwood et al., 2017), which is more pronounced in cancer cells with highly developed lysosomes (Ramírez-García et al., 2019).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.